Researchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2023-08-09_um_04.46.58.png8221766Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-08-03 08:41:002024-07-09 15:11:45Enzyme foams morer active and stable
LSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
https://european-biotechnology.com/wp-content/uploads/2024/04/Neuraxapharm.jpg4451440Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-08-01 16:10:462024-07-09 15:06:53Neuraxpharm pays US$650m for MS drug commercialisation
Milan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders.
siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T
The EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.
Enzyme foams morer active and stable
Latest NewsResearchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.
Bavarian Nordic A/S bags US$120m for smallpox vaccine
Latest NewsBavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government.
PureTech Health gets US$11.4m to advance LYT-300
Latest NewsLSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
Neuraxpharm pays US$650m for MS drug commercialisation
Latest NewsTG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
Mithra Pharmaceuticals SA in €17m licencing deal
Latest NewsMithra and Searchlight Pharma have inked a licensing deal for Donesta commercialisation in Canada.
Bacterial-fungal consortium denitrifies wastewater by 100%
Latest NewsA German-Chinese reasearch consortium has identified a highly active denitrifying microbial consortium that denitrifies wastewater by almost 100%.
Retinopathy: Golgi and Breye join forces
Latest NewsMilan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders.
NK cell therapy company NK:IO raises seed money
Latest NewsBritish NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.
Alnylam in US$2.8bn biobucks deal with Roche
Latest NewssiRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T
Resistance blocker of immune checkpoint inhibitors gets patented
Latest NewsThe EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.